Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Flexus Biosciences
Biotech
Bristol-Myers drops phase 3 trials of $800M IDO drug
The studies are the latest dominoes to fall following the failure of Incyte’s rival IDO drug to move the needle in a pivotal trial.
Nick Paul Taylor
May 1, 2018 7:56am
Celgene, GV-backed FLX gets off $60M round, kick-starts trials
Dec 21, 2017 8:00am
Bristol-Myers posts early data on IDO1-checkpoint inhibitor combo
Nov 10, 2017 9:28am
Celgene-backed FLX picks CCR4 antagonist for clinical trials
Sep 21, 2017 9:57am
EXCLUSIVE: Stealthy Arcus emerges with $120M to make personalized I/O therapy a reality
Aug 29, 2016 8:31am
EXCLUSIVE: Celgene, Novartis back Flexus oncology play
May 3, 2016 7:50am
